1. P921: UPDATED EFFICACY AND SAFETY RESULTS OF TECLISTAMAB, A B-CELL MATURATION ANTIGEN X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM MAJESTEC-1. (23rd June 2022) Authors: Martínez-López, J.; Moreau, P.; Usmani, S. Z.; Garfall, A.; van de Donk, N. W.; San-Miguel, J. F.; Oriol, A.; Chari, A.; Karlin, L.; Mateos, M.-V.; Popat, R.; Nooka, A. K.; Sidana, S.; Trancucci, D.; Verona, R.; Girgis, S.; Uhlar, C.; Stephenson, T.; Banerjee, A.; Krishnan, A. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 811 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. S170: DYNAMIC INTERPLAY BETWEEN TUMOR AND MICRO-ENVIRONMENT DURING MYELOMA DISEASE PROGRESSION. (23rd June 2022) Authors: Köse, M. C.; Bergiers, I.; Malfait, M.; Heidrich, B.; De Maeyer, D.; Fourneau, N.; Verbist, B.; Van Houdt, J.; Vanhoof, G.; Verona, R.; Delforge, M.; Depaus, J.; Meuleman, N.; Van Droogenbroeck, J.; Vlummens, P.; Heuck, C. J.; Bahlis, N.; Caers, J.; Casneuf, T. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 71 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. S184: EVALUATING TECLISTAMAB IN PATIENTS WITH RELAPSED/ REFRACTORY MULTIPLE MYELOMA FOLLOWING EXPOSURE TO OTHER B-CELL MATURATION ANTIGEN (BCMA)-TARGETED AGENTS. (23rd June 2022) Authors: Touzeau, C.; Krishnan, A.; Moreau, P.; Perrot, A.; Usmani, S. Z.; Manier, S.; Cavo, M.; Martinez-Chamorro, C.; Nooka, A.; Martin, T.; Karlin, L.; Leleu, X.; Bahlis, N.; Besemer, B.; Pei, L.; Verona, R.; Girgis, S.; Uhlar, C.; Kobos, R.; Garfall, A. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 85 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗